Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07517250) titled 'A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients' on April 1.

Study Type: Observational

Primary Sponsor: Novartis Pharmaceuticals

Condition: Familial Mediterranean Fever Still Disease Systemic Juvenile Idiopathic Arthritis Adult-Onset Still Disease

Recruitment Status: Not recruiting

Date of First Enrollment: April 7, 2026

Target Sample Size: 160

To know more, visit https://clinicaltrials.gov/study/NCT07517250

Published by HT Digital Content Services with permission from Health Daily Digest....